Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

CLDX Jan 2024 85.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
1.61000.0000 (0.00%)
As of 10:42AM EDT. Market open.
Advertisement
Full screen
Previous Close1.6100
Open1.9000
Bid0.0000
Ask5.0000
Strike85.00
Expire Date2024-01-19
Day's Range1.6100 - 1.9000
Contract RangeN/A
Volume2
Open Interest17
  • Zacks

    Celldex Therapeutics (CLDX) Reports Q2 Loss, Lags Revenue Estimates

    Celldex (CLDX) delivered earnings and revenue surprises of -34.88% and 53.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Celldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update

    - Positive interim data from barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria presented at EAACI 2022 - - First patients dosed in Phase 2 chronic urticaria studies - HAMPTON, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update. “In late June, Celldex reported positive interim data from our ongoing Phase 1b study of barzolvolimab in chronic spontane

  • GlobeNewswire

    Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

    HAMPTON, N.J., July 21, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (CIndU) - cold urticaria (ColdU) and symptomatic dermographism (SD). Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity.

Advertisement
Advertisement